Physician profile
David S Ruderman
NPI 1235201377
$3,262.27
in general payments reported to CMS, 2019-2025
12 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,671 · 2020: $54.12 · 2021: $211 · 2022: $237 · 2023: $467 · 2024: $374 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $907.09 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $666.30 | 2019 | |
| Allergan, INC. | $540.64 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $383.70 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $356.24 | 2019-2021 | |
| Axsome Therapeutics, INC. | $120.87 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $104.63 | 2019 | |
| Bausch Health US, LLC | $67.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.17 | 2019 | |
| Adlon Therapeutics L.P. | $25.15 | 2020 | |
| Ironshore Pharmaceuticals INC. | $17.28 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ruderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.